VentriPoint Diagnostics Ltd (VPTDF)

[teq0904]

Attached is the news release we issued today. Here is some background:

1. Dr. Roberto Lang is the past President of the American Society of Echocardiogrpahy (ASE) and the recognized leader in adopting new echo techniques.
2. His group was part of the original clinical trial in RV analysis using the VMS in Pulmonary Hypertension (PAH). He published an excellent article in the Journal of the American Society of Echocardiography, Volume 26, Issue 8 , Pages 860-867. The paper concluded: “Three-dimensional reconstruction of the RV endocardium from 2D transthoracic echocardiographic images obtained in patients with Pulmonary Arterial Hypertension (PAH), as accomplished by Knowledge-Based Reconstruction (KBR), is feasible, accurate, and reproducible”. (note: KBR is a scientific term for VMS).
3. Roberto was one of the leading doctors who encouraged us to expand the VMS to include all 4 chambers of the heart and not just the RV to address the unmet need in many heart conditions.
4. He remains very supportive of the VMS+ and will now go forward to verify the system is feasible, accurate, and reproducible for all 4 chambers of the heart in a wide range of patients (not just PAH). We have proven to the FDA that the VMS+ is accurate and reliable, but we did this ourselves, and it needs independent verification, which the University of Chicago will provide.
5. His target is to get this done to submit it to the Annual Scientific Congress of the ASE by February.
6. Having the endorsement of the leading cardiologists will facilitate the widespread adoption of the VMS+.
6. We will be announcing other leading centres with the same target to present the VMS+ results in selected patient types at the ASE meeting, which is the largest annual gathering of echocardiographers.